Get the Stockscreener App
6.11
3.04%
0.18
Diamedica Therapeutics Inc stock is traded at $6.11, with a volume of 255.86K.
It is up +3.04% in the last 24 hours and up +32.83% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$5.93
Open:
$5.99
24h Volume:
255.86K
Relative Volume:
0.86
Market Cap:
$315.82M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-11.53
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
+1.33%
1M Performance:
+32.83%
6M Performance:
-6.14%
1Y Performance:
+53.52%
1-Day Range:
$5.93
$6.18
1-Week Range:
$5.68
$6.18
52-Week Range:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.11 | 297.73M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
How high can DiaMedica Therapeutics Inc. stock goWeekly Trend Recap & Verified Short-Term Plans - Newser
Applying Elliott Wave Theory to DiaMedica Therapeutics Inc.2025 Trade Ideas & Fast Exit and Entry Trade Guides - Newser
What’s the recovery path for long term holders of DiaMedica Therapeutics Inc.2025 Pullback Review & Risk Controlled Daily Plans - Newser
Full technical analysis of DiaMedica Therapeutics Inc. stockMarket Sentiment Report & Free Daily Entry Point Trade Alerts - Newser
Intraday pattern recognizer results for DiaMedica Therapeutics Inc.Weekly Market Outlook & Daily Profit Focused Screening - Newser
Pattern recognition hints at DiaMedica Therapeutics Inc. upsideTrade Risk Report & Weekly Top Gainers Trade List - Newser
Statistical indicators supporting DiaMedica Therapeutics Inc.’s strength2025 Technical Overview & Safe Capital Growth Tips - Newser
Technical signs of recovery in DiaMedica Therapeutics Inc.Market Performance Summary & Capital Protection Trading Alerts - Newser
DiaMedica Therapeutics (NASDAQ:DMAC) Receives Buy Rating from HC Wainwright - MarketBeat
Can momentum traders help lift DiaMedica Therapeutics Inc.July 2025 Breakouts & Smart Money Movement Tracker - Newser
DiaMedica Therapeutics Inc. stock chart pattern explainedQuarterly Profit Summary & Real-Time Buy Zone Alerts - Newser
Technical analysis overview for DiaMedica Therapeutics Inc. stockPortfolio Update Summary & Short-Term Trading Alerts - Newser
Can swing trading help recover from DiaMedica Therapeutics Inc. lossesWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have had a fantastic week as stock increased 26%, and they haven't stopped buying - simplywall.st
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - Zacks Investment Research
Will DiaMedica Therapeutics Inc. see short term momentumNew Guidance & Breakout Confirmation Trade Signals - Newser
How to forecast DiaMedica Therapeutics Inc. trends using time seriesDollar Strength & Long-Term Growth Portfolio Plans - Newser
Is DiaMedica Therapeutics Inc. stock ready for a breakout2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - Newser
What makes DiaMedica Therapeutics Inc. stock price move sharplyPortfolio Value Summary & Stepwise Swing Trade Plans - Newser
Volume spikes in DiaMedica Therapeutics Inc. stock – what they meanGDP Growth & Stock Portfolio Risk Control - Newser
Can machine learning forecast DiaMedica Therapeutics Inc. recoveryTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - Newser
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World
Identifying reversal signals in DiaMedica Therapeutics Inc.Product Launch & Accurate Technical Buy Alerts - Newser
Intrinsic Value of DiaMedica Therapeutics Inc. Stock: Is It Undervalued or OvervaluedJuly 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
Multi factor analysis applied to DiaMedica Therapeutics Inc.Insider Selling & Consistent Profit Alerts - Newser
Custom strategy builders for tracking DiaMedica Therapeutics Inc.Market Risk Summary & Community Consensus Picks - Newser
What indicators show strength in DiaMedica Therapeutics Inc.Analyst Downgrade & Risk Managed Investment Signals - Newser
What to expect from DiaMedica Therapeutics Inc. in the next 30 daysGap Up & Reliable Entry Point Trade Alerts - Newser
Is this a good reentry point in DiaMedica Therapeutics Inc.July 2025 Earnings & Reliable Entry Point Alerts - Newser
What’s the MACD signal for DiaMedica Therapeutics Inc.Entry Point & Weekly Watchlist for Hot Stocks - classian.co.kr
Chart based exit strategy for DiaMedica Therapeutics Inc.New Guidance & Verified Momentum Stock Watchlist - Newser
DiaMedica Therapeutics Inc (DMAC) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2025 Earnings Call Transcript - Insider Monkey
DiaMedica advances DM199 programs with $60M cash runway and expanded clinical trials - MSN
DiaMedica Therapeutics Advances with Positive Trials and Funding - TipRanks
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Diamedica Therapeutics Inc Stock (DMAC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Von Koch Thomas | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
2,857,142 |
9,999,997 |
8,383,577 |
| JACINTO RICHARD II | 10% Owner |
Jul 23 '25 |
Buy |
3.50 |
400,000 |
1,400,000 |
4,958,823 |
| Pilnik Richard D. | Director |
Apr 07 '25 |
Option Exercise |
2.11 |
24,000 |
50,640 |
312,995 |
| Giuffre Randall Michael | Director |
Feb 13 '25 |
Option Exercise |
2.56 |
17,000 |
43,570 |
392,412 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):